We did not provide further information on patients with pathological grade 4 astrocytoma, specifically IDH‐mutant glioblastoma, or patients with molecular grade 4 astrocytoma with CDKN2A/B homozygous deletion. This evidence concerns the gene CDKN2A and glioblastoma.